Literature DB >> 12920036

Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells.

Joya Chandra1, Jennifer Hackbarth, Son Le, David Loegering, Nancy Bone, Laura M Bruzek, Ven L Narayanan, Alex A Adjei, Neil E Kay, Ayalew Tefferi, Judith E Karp, Edward A Sausville, Scott H Kaufmann.   

Abstract

Adaphostin (NSC 680410), an analog of the tyrphostin AG957, was previously shown to induce Bcr/abl down-regulation followed by loss of clonogenic survival in chronic myelogenous leukemia (CML) cell lines and clinical samples. Adaphostin demonstrated selectivity for CML myeloid progenitors in vitro and remained active in K562 cells selected for imatinib mesylate resistance. In the present study, the mechanism of action of adaphostin was investigated in greater detail in vitro. Initial studies demonstrated that adaphostin induced apoptosis in a variety of Bcr/abl- cells, including acute myelogenous leukemia (AML) blasts and cell lines as well as chronic lymphocytic leukemia (CLL) samples. Further study demonstrated that adaphostin caused intracellular peroxide production followed by DNA strand breaks and, in cells containing wild-type p53, a typical DNA damage response consisting of p53 phosphorylation and up-regulation. Importantly, the antioxidant N-acetylcysteine (NAC) blunted these events, whereas glutathione depletion with buthionine sulfoximine (BSO) augmented them. Collectively, these results not only outline a mechanism by which adaphostin can damage both myeloid and lymphoid leukemia cells, but also indicate that this novel agent might have a broader spectrum of activity than originally envisioned.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920036     DOI: 10.1182/blood-2003-02-0562

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study.

Authors:  Raphaël Beck; Rozangela Curi Pedrosa; Nicolas Dejeans; Christophe Glorieux; Philippe Levêque; Bernard Gallez; Henryk Taper; Stéphane Eeckhoudt; Laurent Knoops; Pedro Buc Calderon; Julien Verrax
Journal:  Invest New Drugs       Date:  2010-05-08       Impact factor: 3.850

2.  Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.

Authors:  Nilsa Rivera-Del Valle; Tiewei Cheng; Mary E Irwin; Hayley Donnella; Melissa M Singh; Joya Chandra
Journal:  Cancer Chemother Pharmacol       Date:  2018-01-08       Impact factor: 3.333

3.  Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.

Authors:  Joya Chandra; Jeannette Tracy; David Loegering; Karen Flatten; Srdan Verstovsek; Miloslav Beran; Mercedes Gorre; Zeev Estrov; Nicholas Donato; Moshe Talpaz; Charles Sawyers; Kapil Bhalla; Judith Karp; Edward Sausville; Scott H Kaufmann
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

Review 4.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

5.  Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs.

Authors:  Claudia P Miller; Christa A Manton; Randal Hale; LaKeisha Debose; Venkat R Macherla; Barbara C Potts; Michael A Palladino; Joya Chandra
Journal:  Chem Biol Interact       Date:  2011-08-16       Impact factor: 5.192

Review 6.  Redox control of leukemia: from molecular mechanisms to therapeutic opportunities.

Authors:  Mary E Irwin; Nilsa Rivera-Del Valle; Joya Chandra
Journal:  Antioxid Redox Signal       Date:  2012-09-28       Impact factor: 8.401

7.  Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.

Authors:  Claudia P Miller; Sharmistha Rudra; Michael J Keating; William G Wierda; Michael Palladino; Joya Chandra
Journal:  Blood       Date:  2009-01-30       Impact factor: 22.113

8.  PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells.

Authors:  Nilsa Rivera-Del Valle; Shan Gao; Claudia P Miller; Joy Fulbright; Carolina Gonzales; Mint Sirisawad; Susanne Steggerda; Jennifer Wheler; Sriram Balasubramanian; Joya Chandra
Journal:  Int J Cell Biol       Date:  2010-01-18

9.  Adaphostin toxicity in a sensitive non-small cell lung cancer model is mediated through Nrf2 signaling and heme oxygenase 1.

Authors:  Nicole D Fer; Robert H Shoemaker; Anne Monks
Journal:  J Exp Clin Cancer Res       Date:  2010-07-09

10.  Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells.

Authors:  Shan Gao; Aaron Mobley; Claudia Miller; Jessica Boklan; Joya Chandra
Journal:  Leuk Res       Date:  2007-11-26       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.